TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18809423

Group type: EXPERIMENTAL
Intervention: Inverted face cues in a visual cueing paradigm (Experiment 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Upright and inverted face cues (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manipulation of predictiveness of cues (Experiment 3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Replication of Experiment 2 with extended stimulus set (Experiment 4)
Number of subjects: 0
Study: 16894407

Group type: EXPERIMENTAL
Intervention: Tramadol Contramid once-daily 200 mg tablets
Number of subjects: 26

Group type: COMPARATOR
Intervention: Zytram 200 mg tablets
Number of subjects: 26
Study: 12509627

Group type: EXPERIMENTAL
Intervention: Doloteffin (60 mg of harpagoside daily for 6 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Rofecoxib (12.5 mg/day for 6 weeks)
Number of subjects: 88
Study: 10994324

Group type: EXPERIMENTAL
Intervention: Collagen
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Tranexamic acid mouthwash
Number of subjects: 124

Group type: COMPARATOR
Intervention: Mucosal flaps
Number of subjects: 124
Study: 8706482

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg administered intravenously)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (equivalent administered intravenously)
Number of subjects: 50
Study: 1714011

Group type: EXPERIMENTAL
Intervention: ISDN + NAC (600 mg q.i.d.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: ISDN + placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: ISDN + NAC
Number of subjects: 7
Study: 6178382

Group type: EXPERIMENTAL
Intervention: Clorgyline, 5 to 10 mg every or every other day
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 30897012

Group type: EXPERIMENTAL
Intervention: Mixed nuts
Number of subjects: 54

Group type: COMPARATOR
Intervention: Pretzels
Number of subjects: 54
Study: 29543659

Group type: EXPERIMENTAL
Intervention: Maladaptive pain-coping strategy of guarding
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Pain catastrophizing appraisal measures
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Maladaptive responses (guarding, resting, pain catastrophizing)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Adaptive responses
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Maladaptive responses
Number of subjects: 384
Study: 28797611

Group type: EXPERIMENTAL
Intervention: Video training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Written instructions
Number of subjects: 50
Study: 26037176

Group type: EXPERIMENTAL
Intervention: 12-week home based exercise program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 23237575

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise for 8 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Group counselling for 8 weeks
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise and group counselling combined
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Group counselling first followed by exercise
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Exercise first followed by group counselling
Number of subjects: 17
Study: 20602503

Group type: EXPERIMENTAL
Intervention: Structured bike and strengthening regimen (bike/strengthening group, 58 patients)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Simpler walking and breathing regimen (walk/breathing group, 54 patients)
Number of subjects: 112
Study: 18238962

Group type: EXPERIMENTAL
Intervention: Contraceptive ring
Number of subjects: 500

Group type: COMPARATOR
Intervention: Contraceptive patch
Number of subjects: 500
Study: 16603285

Group type: EXPERIMENTAL
Intervention: Patella resurfacing (n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: No patella resurfacing (n=25)
Number of subjects: 50
Study: 14660155

Group type: EXPERIMENTAL
Intervention: Men with alcohol dependence and PTSD
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Women with alcohol dependence and PTSD
Number of subjects: 84

Group type: COMPARATOR
Intervention: Women
Number of subjects: 84
Study: 10967698

Group type: EXPERIMENTAL
Intervention: Prazosin (sustained-release) 2.5 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 100
Study: 8790198

Group type: EXPERIMENTAL
Intervention: 123I‐VIP (150‐200 MBq; 1 microgram)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 111In‐CYT‐103 (150 MBq; 1 mg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 123I‐VIP
Number of subjects: 50

Group type: COMPARATOR
Intervention: 111In‐CYT‐103
Number of subjects: 50
Study: 8218966

Group type: EXPERIMENTAL
Intervention: Intramuscular tenoxicam (20 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral tenoxicam (20 mg)
Number of subjects: 24
Study: 3799499

Group type: EXPERIMENTAL
Intervention: Paffenbarger survey
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Modified Paffenbarger
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Large-scale integrated activity monitor (LSI)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Caloric intake
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Baecke survey
Number of subjects: 255
Study: 28628251

Group type: COMPARATOR
Intervention: Single-drug regimens (Vemurafenib, Dabrafenib, Nivolumab)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Double-drug regimens (Dabrafenib + Trametinib, Nivolumab + Ipilimumab, Vemurafenib + Cobimetinib)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single-drug regimens (Vemurafenib, Dabrafenib)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Double-drug regimens (Dabrafenib + Trametinib, Vemurafenib + Cobimetinib)
Number of subjects: 16
Study: 27368882

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonal therapy and breast surgery
Number of subjects: 431
Study: 24274384

Group type: EXPERIMENTAL
Intervention: Greater magnitude stimuli (number, size, color saturation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manipulations to the direction of the sequence
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ordered (continuous) or nonordered (discontinuous) pattern trajectories
Number of subjects: 0
Study: 24673050

Group type: EXPERIMENTAL
Intervention: Acupoint catgut implantation combined with artificial periodic therapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Artificial periodic therapy with oral administration of medroxyprogesterone acetate tablets
Number of subjects: 65
Study: 22467989

Group type: EXPERIMENTAL
Intervention: Room temperature of 16°C
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Room temperature of 20°C
Number of subjects: 40

Group type: COMPARATOR
Intervention: Room temperature of 24°C
Number of subjects: 40
Study: 20973708

Group type: EXPERIMENTAL
Intervention: Ritalin(®) LA 20 mg
Number of subjects: 147

Group type: COMPARATOR
Intervention: Medikinet(®) Retard
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 17963813

Group type: EXPERIMENTAL
Intervention: Masked primes with a target-congruent shape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Masked shape-incongruent primes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual rotation detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shapes of masked stimuli
Number of subjects: 0
Study: 15582637

Group type: EXPERIMENTAL
Intervention: Reminiscence intervention (weekly for 4 months)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (no reminiscence intervention)
Number of subjects: 94
Study: 12397268

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte rehydration solution
Number of subjects: 168

Group type: COMPARATOR
Intervention: Regular clear fluids
Number of subjects: 168
Study: 10522131

Group type: EXPERIMENTAL
Intervention: Dobutamine (2.5‐3 micrograms/kg/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No dobutamine
Number of subjects: 24
Study: 8978228

Group type: EXPERIMENTAL
Intervention: Psychiatric disorder diagnosis
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Substance misuse diagnosis
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Neurotic illness diagnosis
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Personality disorder diagnosis
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Psychosis diagnosis
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Other and uncertain diagnoses
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Immediate treatment need
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Transfer to NHS bed
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Treatment by prison health care services
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Motivational interviewing for substance misuse
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Therapeutic community placement
Number of subjects: 750
Study: 1321859

Group type: EXPERIMENTAL
Intervention: Oka strain live attenuated varicella-zoster virus (VZV) vaccine, administered subcutaneously at doses varying from 1100 to 12,000 pfu, with one cohort receiving 3000 pfu and a 3000 pfu booster 3 months later.
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Oka strain live attenuated varicella-zoster virus (VZV) vaccine
Number of subjects: 202
Study: 6376042

Group type: EXPERIMENTAL
Intervention: 200 IU Calcitonin‐Sandoz
Number of subjects: 20
Study: 29189266

Group type: COMPARATOR
Intervention: Air Loss of Resistance (ALOR) technique
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Saline Loss of Resistance (SLOR) technique
Number of subjects: 376
Study: 27048152

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 183
Study: 24118368

Group type: COMPARATOR
Intervention: One-piece titanium implants
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One-piece zirconia implants
Number of subjects: 24
Study: 22632588

Group type: EXPERIMENTAL
Intervention: Lumbar SNAG (sustained natural apophyseal glide)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sham technique (simulated SNAG without applying force)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (static sitting position)
Number of subjects: 45
Study: 20439247

Group type: EXPERIMENTAL
Intervention: Meal tolerance test (high-glucose load meal)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Body composition measurement
Number of subjects: 15
Study: 17363746

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes support and education (DSE)
Number of subjects: 5145
Study: 16325139

Group type: EXPERIMENTAL
Intervention: Loss-framed message intervention
Number of subjects: 1104

Group type: COMPARATOR
Intervention: Usual communication (control)
Number of subjects: 1104
Study: 12075219

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.4 mg/mL applied for 4 minutes
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline control applied for 4 minutes
Number of subjects: 55
Study: 9457334

Group type: EXPERIMENTAL
Intervention: Duplex ultrasound
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Liquid crystal contact thermography (LCCT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Phlebography (control)
Number of subjects: 112
Study: 8545862

Group type: EXPERIMENTAL
Intervention: Transplantation
Number of subjects: 6400

Group type: COMPARATOR
Intervention: Dialysis
Number of subjects: 6400
Study: 1477004

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 6389378

Group type: EXPERIMENTAL
Intervention: Oral bumetanide
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intravenous bumetanide
Number of subjects: 44

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 44
Study: 31349792

Group type: EXPERIMENTAL
Intervention: 14-day ECG monitoring patch (Zio® Patch, iRhythm Technologies)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Short-duration Holter monitoring
Number of subjects: 116
Study: 28525614

Group type: EXPERIMENTAL
Intervention: 40 mg lidocaine (group RL40)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: 1.2 mg/kg lidocaine (group LL1.2)
Number of subjects: 1095

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg lidocaine
Number of subjects: 1095

Group type: COMPARATOR
Intervention: Normal saline (group PR)
Number of subjects: 1095
Study: 27516476

Group type: EXPERIMENTAL
Intervention: PI-only ART (lopinavir/ritonavir/saquinavir) for 24 weeks
Number of subjects: 48
Study: 27128611

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21922171

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 20621270

Group type: EXPERIMENTAL
Intervention: Persica extract chewing gum with scaling (S+/P+)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo chewing gum with scaling (S+/P-)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Persica extract chewing gum without scaling (S-/P+)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo chewing gum without scaling (S-/P-)
Number of subjects: 72
Study: 17394474

Group type: EXPERIMENTAL
Intervention: Eccentric exercises
Number of subjects: 53

Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 53
Study: 16386524

Group type: EXPERIMENTAL
Intervention: Plasmapheresis (PP) and intravenous immunoglobulin (IVIG)
Number of subjects: 7
Study: 12048292

Group type: COMPARATOR
Intervention: Methotrexate (MTX) plus placebo (n=39)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus folic acid (n=35)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus folinic acid (n=39)
Number of subjects: 113
Study: 10361625

Group type: EXPERIMENTAL
Intervention: Mifepristone-misoprostol medical abortion
Number of subjects: 1373

Group type: COMPARATOR
Intervention: Surgical abortion
Number of subjects: 1373
Study: 7608861

Group type: EXPERIMENTAL
Intervention: Accurate attitude reporting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Misreported attitudes (neutral or negative)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attitude reports and LPPs to negative, neutral, and positive stimuli preceded by negative stimuli
Number of subjects: 0
Study: 2793391

Group type: EXPERIMENTAL
Intervention: Ioversol 320
Number of subjects: 24

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study: 337982

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate, 200 mg, intramuscularly weekly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30797761

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29096835

Group type: EXPERIMENTAL
Intervention: Lipoprotein apheresis (LA) treatment, weekly for 2 years
Number of subjects: 150

Group type: COMPARATOR
Intervention: Maximum tolerated lipid lowering therapy (control group)
Number of subjects: 150
Study: 25862777

Group type: EXPERIMENTAL
Intervention: Intensive RRT
Number of subjects: 817

Group type: COMPARATOR
Intervention: Less-intensive RRT
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Intensive RRT with high day 1 biomarkers (IL-6, macrophage migration inhibitory factor, TNFR-I)
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Intensive RRT with low day 1 biomarkers
Number of subjects: 817

Group type: EXPERIMENTAL
Intervention: Elevated biomarkers on day 8 among 476 participants
Number of subjects: 817
Study: 23324699

Group type: EXPERIMENTAL
Intervention: Training program providing additional knowledge and demonstrating 'how-to' apply recommendations at the workstation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-existing office ergonomic checklist training
Number of subjects: 0
Study: 21498149

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC) dosed once daily
Number of subjects: 1363

Group type: COMPARATOR
Intervention: Lamivudine (3TC) dosed twice daily
Number of subjects: 1363

Group type: EXPERIMENTAL
Intervention: Emtricitabine (FTC)
Number of subjects: 1363

Group type: COMPARATOR
Intervention: Lamivudine (3TC)
Number of subjects: 1363
Study: 19249153

Group type: EXPERIMENTAL
Intervention: Intermittent hormonal therapy (IHT) with cyproterone acetate (CPA) 200mg for 2 weeks and then monthly depot injections of a luteinising hormone-releasing hormone (LHRH) analogue plus 200mg of CPA daily during induction. Patients randomised to the intermittent arm ceased treatment.
Number of subjects: 766

Group type: COMPARATOR
Intervention: Continuous therapy with 200mg of CPA daily plus an LHRH analogue.
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Intermittent hormonal therapy (IHT)
Number of subjects: 766

Group type: COMPARATOR
Intervention: Continuous therapy
Number of subjects: 766
Study: 16915302

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (STSC)
Number of subjects: 1704
Study: 15521689

Group type: EXPERIMENTAL
Intervention: Categorical perception near vertical orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous perception near horizontal orientation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sorting oriented line stimuli into categories
Number of subjects: 0
Study: 11508043

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 30
Study: 9383182

Group type: EXPERIMENTAL
Intervention: Metoprolol (50-250 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Prazosin (3-20 mg/day)
Number of subjects: 18
Study: 8304581

Group type: EXPERIMENTAL
Intervention: Wobenzym (proteolytic, glycolytic, and lipolytic enzymes and rutoside)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 3684175

Group type: EXPERIMENTAL
Intervention: aminoglutethimide 1000 mg/day + hydrocortisone 20 mg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: aminoglutethimide 250 mg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: aminoglutethimide (both dosages)
Number of subjects: 29
Study: 29556903

Group type: EXPERIMENTAL
Intervention: e-alert group
Number of subjects: 875

Group type: COMPARATOR
Intervention: non-e-alert group
Number of subjects: 875
Study: 27011002

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) - once-daily (long-acting) for 4 weeks
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) - highest dose
Number of subjects: 163
Study: 23959630

Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SrRan) 2 g per day
Number of subjects: 387

Group type: COMPARATOR
Intervention: Alendronate (ALN) 70 mg per week
Number of subjects: 387
Study: 23876458

Group type: EXPERIMENTAL
Intervention: Boceprevir
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1020
Study: 20226890

Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT-6 vaccine with IC31 adjuvant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ag85B-ESAT-6 vaccine without IC31 adjuvant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18344850

Group type: EXPERIMENTAL
Intervention: Eperisone hydrochloride (EMPP) for 4 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: McKenzie therapy
Number of subjects: 74

Group type: COMPARATOR
Intervention: Physical therapy only (control)
Number of subjects: 74
Study: 15809409

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Continuation medication
Number of subjects: 104
Study: 12584366

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors
Number of subjects: 6083

Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors (among male subjects)
Number of subjects: 6083

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme (ACE) inhibitors (among female subjects)
Number of subjects: 6083
Study: 10321419

Group type: EXPERIMENTAL
Intervention: Nabumetone 2000 mg/d
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sulindac 400 mg/d
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8723378

Group type: EXPERIMENTAL
Intervention: Controlled release L-DOPA/carbidopa (100/25 mg)
Number of subjects: 5
Study: 1862734

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study: 6412390

Group type: EXPERIMENTAL
Intervention: Sodium heparin 5000 IU subcutaneously every 12 hours for 7 days
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Semi-synthetic heparin analogue (SSHA) 75 mg subcutaneously every 12 hours for 7 days
Number of subjects: 21
Study: 31957555

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplement (2000 IU/day)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31515191

Group type: EXPERIMENTAL
Intervention: TAP flap
Number of subjects: 50

Group type: COMPARATOR
Intervention: LD flap
Number of subjects: 50
Study: 27910150

Group type: EXPERIMENTAL
Intervention: ONO-2952 20 mg
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ONO-2952 60 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 26625090

Group type: EXPERIMENTAL
Intervention: Challenging parenting behaviour by fathers
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Challenging parenting behaviour by mothers
Number of subjects: 164

Group type: COMPARATOR
Intervention: Children with anxiety disorder (n=74)
Number of subjects: 164
Study: 24901279

Group type: EXPERIMENTAL
Intervention: Moxibustion with acupuncture
Number of subjects: 328

Group type: COMPARATOR
Intervention: Placebo (inactivated laser treatment)
Number of subjects: 328